早期帕金森病中阿尔茨海默病脑脊液生物标志物的演变
本研究在PPMI队列中纵向分析了416例早期帕金森病患者和192例健康对照的脑脊液Aβ42、t-tau和p-tau水平,随访3年。发现帕金森病患者基线脑脊液t-tau、p-tau和Aβ42均低于健康对照,且3年内Aβ42和p-tau下降更明显,基线Aβ42可预测认知、自主神经和运动功能的轻微下降。
要点
- 早期帕金森病患者基线脑脊液Aβ42、t-tau和p-tau水平低于健康对照。
- 帕金森病患者3年内脑脊液Aβ42和p-tau下降幅度大于健康对照。
- 基线脑脊液Aβ42可预测早期帕金森病认知、自主神经和运动功能的轻微下降。
核心结论
- 基线脑脊液阿尔茨海默病生物标志物可能对早期帕金森病具有预后价值。
- 3年内这些标志物的动态变化虽幅度不大,但提示帕金森病的生物标志物谱可能偏离健康衰老。
研究设计与样本
- 纵向队列研究,纳入PPMI中随访至多3年的帕金森病患者416例和健康对照192例。
- 采用Roche Elecsys电化学发光免疫法检测脑脊液Aβ42、t-tau和p-tau(苏氨酸181位点)。
- 使用线性混合效应模型分析纵向脑脊液与临床数据。
主要发现
- 帕金森病患者基线脑脊液t-tau中位数157.7 pg/mL(范围80.9-467.0),低于健康对照的173.5 pg/mL(范围82.0-580.8),p<0.05-0.001。
- 帕金森病患者基线脑脊液p-tau中位数13.4 pg/mL(范围8.0-40.1),低于健康对照的15.4 pg/mL(范围8.1-73.6)。
- 帕金森病患者基线脑脊液Aβ42中位数846.2 pg/mL(范围238.8-3,707.0),低于健康对照的926.5 pg/mL(范围239.1-3,297.0)。
- 帕金森病患者和健康对照中这些生物标志物之间均呈中度至强相关(Rho=0.50-0.97,p<0.001)。
- 31.5%的帕金森病患者基线脑脊液Aβ42病理性降低,其p-tau中位数10.8 pg/mL(范围8.0-32.8),低于27.7%基线Aβ42病理性降低的健康对照的12.8 pg/mL(范围8.2-73.6),p<0.03。
关键数值与推荐
- 第3年时帕金森病患者脑脊液Aβ42下降均值差为-41.83 pg/mL(p=0.03),p-tau下降均值差为-0.38 pg/mL(p=0.03),均大于健康对照。
- 基线脑脊液Aβ42值可预测早期帕金森病认知、自主神经和运动功能的轻微但可测量的下降。
临床怎么用
- 在早期帕金森病中可考虑检测基线脑脊液Aβ42、t-tau和p-tau以辅助预后评估。
- 基线脑脊液Aβ42水平有助于识别认知、自主神经和运动功能下降风险较高的早期帕金森病患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We analyzed the longitudinal profile of Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers in early Parkinson's disease (PD) compared with healthy controls (HCs) and tested baseline CSF biomarkers for prediction of clinical decline in PD. METHODS: Amyloid-β 1 to 42 (Aβ42 ), total tau (t-tau) and phosphorylated tau (p-tau) at the threonine 181 position were measured using the high-precision Roche Elecsys electrochemiluminescence immunoassay in all available CSF samples from longitudinally studied patients with PD (n = 416) and HCs (n = 192) followed for up to 3 years in the Parkinson's Progression Markers Initiative (PPMI). Longitudinal CSF and clinical data were analyzed with linear-mixed effects models. RESULTS: We found patients with PD had lower CSF t-tau (median = 157.7 pg/mL; range = 80.9-467.0); p-tau (median = 13.4 pg/mL; range = 8.0-40.1), and Aβ42 (median = 846.2 pg/mL; range = 238.8-3,707.0) than HCs at baseline (CSF t-tau median = 173.5 pg/mL; range = 82.0-580.8; p-tau median = 15.4 pg/mL; range = 8.1-73.6; and Aβ42 median = 926.5 pg/mL; range = 239.1-3,297.0; p < 0.05-0.001) and a moderate-to-strong correlation among these biomarkers in both patients with PD and HCs (Rho = 0.50-0.97; p < 0.001). Of the patients with PD, 31.5% had pathologically low levels of CSF Aβ42 at baseline and these patients with PD had lower p-tau levels (median = 10.8 pg/mL; range = 8.0-32.8) compared with 27.7% of HCs with pathologically low CSF Aβ42 (CSF p-tau median = 12.8 pg/mL; range 8.2-73.6; p < 0.03). In longitudinal CSF analysis, we found patients with PD had greater decline in CSF Aβ42 (mean difference = -41.83 pg/mL; p = 0.03) and CSF p-tau (mean difference = -0.38 pg/mL; p = 0.03) at year 3 compared with HCs. Baseline CSF Aβ42 values predicted small but measurable decline on cognitive, autonomic, and motor function in early PD. INTERPRETATION: Our data suggest baseline CSF AD biomarkers may have prognostic value in early PD and that the dynamic change of these markers, although modest over a 3-year period, suggest biomarker profiles in PD may deviate from healthy aging. ANN NEUROL 2020;88:574-587.
引用
- Irwin DJ, Fedler J, Coffey CS, et al. Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. Ann Neurol. 2020. PMID: 32542885. doi:10.1002/ana.25811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。